Abstract:Background: Ubiquitin-proteasome system (UPS) is implicated in cancer occurrence and progression. Targeting UPS is emerging as a promising therapeutic target for cancer treatment. Nevertheless, the clinical significance of UPS in hepatocellular carcinoma (HCC) has not been entirely elucidated. Methods: Differentially expressed UPS genes (DEUPS) were screened from LIHC-TCGA datasets. The least absolute shrinkage and selection operator (LASSO) and stepwise multivariate regression analysis were conducted to establish a UPS-based prognostic risk model. The robustness of the risk model was further validated in HCCDB18, GSE14520, and GSE76427 cohorts. Subsequently, immune features, clinicopathologic characteristics, enrichment pathways, and anti-tumor drug sensitivity of the model were further evaluated. Moreover, a nomogram was established to improve the predictive ability of the risk model. Results: Seven UPS-based signatures (ATG10, FBXL7, IPP, MEX3A, SOCS2, TRIM54, and PSMD9) were developed for the prognostic risk model. Individuals with HCC with high-risk scores presented a more dismal prognosis than those with low-risk scores. Moreover, larger tumor size, advanced TNM stage, and tumor grade were observed in the high-risk group. Additionally, cell cycle, ubiquitin-mediated proteolysis, and DNA repair pathways were intimately linked to the risk score. In addition, obvious immune cell infiltration and sensitive drug response were identified in low-risk patients. Furthermore, both nomogram and risk score showed a significant prognosis-predictive ability. Conclusion: Overall, we established a novel UPS-based prognostic risk model in HCC. Our results will facilitate a deep understanding of the functional role of UPS-based signature in HCC and provide a reliable prediction of clinical outcomes and anti-tumor drug responses for patients with HCC.

The Ubiquitin–proteasome System and Its Potential Application in Hepatocellular Carcinoma Therapy

Ubiquitin–proteasome system (UPS) as a target for anticancer treatment

The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy

Comprehensive Analysis of Ubiquitin‐specific Protease 1 Reveals Its Importance in Hepatocellular Carcinoma

Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application

The Role Of The Ubiquitin-Proteasome Pathway In Cancer Development And Treatment

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Expanding the ubiquitin code in pancreatic cancer

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

The Ubiquitin–Proteasome System in Tumor Metabolism

Integrated ubiquitomics characterization of hepatocellular carcinomas